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INTRODUCTION
Diffuse  parenchymal  lung  disease  is  a  term  given  to  a 
heterogeneous group of clinical entities  that share the following features: 
dyspnea as the main symptom; hypoxemia; restrictive Ventilatory defect 
pattern  in  pulmonary  function  tests;  and  the  presence  of  reticular, 
nodular,  reticulonodular,  or  ground glass-appearing infiltrates  on chest 
roentgenogram.  However,  “interstitial  lung  disease”  is  a  misnomer, 
because  this  condition  affects  not  only  the  interstitium  but  also  the 
alveolar  space  and  sometimes  the  airways.  So  the  term  diffuse 
parenchymal lung disease (DPLD) is more appropriate1.
Under the heading of diffuse parenchymal lung disease, there are 
diverse  aetiologies’  that  lead  to  similar  histologic  patterns2.  These 
patterns are the main determinants of the clinical outcome of the patients 
and are also important in the differential  diagnosis,  mainly from other 
diseases that also affect interstitial compartment of the lungs.
Diffuse  Parenchymal  Lung  disease  is  the  fourth  most  common 
disease of the lungs, following chronic obstructive lung disease, asthma, 
and lung cancer3.  Patients with diffuse interstitial lung diseases (DPLD) 
are  challenging  to  treat.  Many  patients  with  DPLD  have  inadequate 
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information  about  the  disease  process,  an  imprecise  diagnosis, 
unsatisfactory  treatment  or  unacceptable  side  effects  associated  with 
therapy, and poorly controlled symptoms of progressive illness. 
Establishing an accurate diagnosis is necessary so that the patient and his/
her family can be provided with reasonable expectations about prognosis 
and outcome from therapy. 
 Lung biopsy is required to establish the aetiology and stage 
of interstitial lung disease (DPLD). Lung biopsy is indicated for the 
following purposes4:
• To  provide  a  specific  diagnosis.  This  is  especially 
desirable in a patient with atypical features (age <50 years, 
fever,  weight  loss,  haemoptysis,  signs  of  vasculitis);  a 
progressive course; a normal, atypical, or rapidly changing 
chest radiograph or high resolution CT scan; unexplained 
extra  pulmonary  manifestations;  or  pulmonary  vascular 
disease of unclear origin.
• To assess disease activity
• To  exclude  neoplastic  and  infectious  processes  that 
occasionally mimic chronic, progressive interstitial disease
• To  identify  a  more  treatable  process  than  originally 
suspected
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• To  make  a  definitive  diagnosis  and  predict  prognosis 
before proceeding with therapies which may have serious 
side effects
s
Lung  tissue  is  obtained  via  fiberoptic  bronchoscopy  with 
transbronchial biopsy, open thoracotomy, or video-assisted thoracoscopic 
lung  surgery  (VATS).  All  are  subject  to  sampling  error  because  the 
processes are often patchy and the sample sizes may be small5. 
Open  lung  biopsy  (OLB)  is  considered  the  best  method  for 
diagnosing  parenchymal  lung  disease.  Nevertheless,  despite  recent 
advances in surgical techniques (ie, thoracoscopy), it is still considered an 
invasive procedure requiring general anaesthesia and is associated with 
substantial morbidity and mortality6
Open  or  thoracoscopic  lung  biopsy  is  appropriate  when 
investigating diffuse disease in which either transbronchial lung biopsy 
has failed to establish the diagnosis or the clinical features suggest from 
the outset that a larger piece of tissue might be required. 
Transbronchial  lung  biopsy — Fiberoptic  bronchoscopy  with 
transbronchial  lung  biopsy  is  often  the  initial  procedure  of  choice, 
especially  when  sarcoidosis,  lymphangitic  carcinomatosis,  eosinophilic 
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pneumonia, Good pasture’s syndrome, or infection is suspected. TBLB 
via  flexible  bronchoscopy  is  a  safe  procedure  with  a  low  rate  of 
complications7. Transbronchial biopsy can be performed at the same time 
as  BAL  and  adds  only  a  slight  additional  risk  of  bleeding  and 
pneumothorax.  For  example,  the  combination  of  BAL, transbronchial 
lung biopsy, and transbronchial mediastinal lymph node aspiration has 
proved  to  be  very  sensitive  for  the  diagnosis  of  sarcoidosis,  as 
demonstrated by Leonard and colleagues in 13 patients with suspected 
sarcoidosis; the combination provided a sensitivity of 100%.
Although  an  argument  can  be   made  for  the  ‘blind’  use  of 
corticosteroid therapy in such situations, in that the prognosis of many 
such diffuse lung diseases is related more closely to response to steroids 
than  to  histological  appearance,  it  is  nevertheless  standard  practice  to 
obtain  tissue  in  these  circumstances,  a  procedure  likely  to  put  the 
diagnosis on a firm footing and that should at the very least avoid the 
unusual but potentially disastrous confusion of sarcoidosis with miliary 
tuberculosis
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AIM AND OBJECTIVE
To determine the Role of Transbronchial lung Biopsy as diagnostic 
procedure in Patients with diffuse parenchymal Lung Diseases.   
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REVIEW OF LITERATURE
The diffuse parenchymal lung diseases (DPLD) are a group 
of  heterogeneous  entities  grouped  together  because  of  similar 
clinical, physiologic, radiologic and pathologic manifestations.
Under  normal  conditions,  small  numbers  of  interstitial 
macrophages,  fibroblasts,  and  myofibroblasts  (cellular 
components)  reside  within  the  interstitium.  Other  components 
(non-cellular) of the interstitium include the matrix proteins of the 
lung, consisting of a) collagen-related macromolecules and the b) 
non-collagenous  proteins  such  as  fibronectin  and  laminin. 
Interstitial  fibrosis  appears  after  injury  occurs  to  the  gas-
exchanging  units,  increasing  alveolar  permeability,  enabling  the 
serum contents to enter the alveolar spaces. 
Fibroblastic proliferation and excessive collagen deposition, 
the histologic hallmarks of interstitial lung disease, occur either as 
a  direct  result  of  the injury,  as  a  result  of  an inflammatory cell 
response that releases pro-inflammatory and profibrotic cytokines, 
or as a consequence of the regenerative and reparative processes 
taking place at the epithelial and endothelial surfaces. 
Over 150 separate entities are included in this classification 
with  much confusion in  the nomenclature8.  The term “interstitial 
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lung  disease”  is  a  misnomer  because  these  disorders  have 
extensive alteration of 
airways, lung parenchyma, blood vessels and pleura as well and 
“diffuse  parenchymal  lung  disease  (DPLD)  is  more  appropriate. 
The  diagnosis  of  individual  disease  is  made  after  a  careful 
consideration  of  clinical  (thorough  history  and  examination) 
features, radiology and pathology. 
The clinician plays a central role in the evaluation of these 
entities  because  a  comprehensive  history  and  examination  are 
central  to  the evaluation of  these entities.  The large number of 
individual entities necessitates a reductionist approach by grouping 
them according to clinical  (etiologic,  physiologic)  or  pathological 
features.  Clinical  sub-categorization  enables  easy  evaluation; 
pathologic sub-classification predicts response.
Classification
1. I. Clinical classification:9,10,11,12 
DPLD’S can be classified into seven major sub-groups etiologically 
1. Idiopathic interstitial pneumonias 
2. Collagen vascular-disease associated 
3. Iatrogenic (drug/ radiation/ toxin) related 
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4. Inherited causes 
5. Granulomatous diseases (known/ idiopathic) 
6. Specific entities 
7. Environmental/ occupational 
E
II. Classification according to response: 
1. Good response: 
Eosinophilic  pneumonia/  drug  induced/  hypersensitivity 
pneumonitis/  vasculitis/organizing  pneumonias/  Lymphoid  interstitial 
pneumonia/Pulmonary alveolar protenosis/ sarcoidosis 
2. Sometimes times responsive: 
Diffuse  alveolar  damage/  Granulomatous  lung  disease  /  Diffuse 
alveolar haemorrhage. 
3. Poorly responsive: 
IPF/  Lymphangiomyomatosis/Pulmonary  Langerhans  –  cell 
histiocytosis/Asbestosis 
A  good,  detailed  and  structured  history  and  clinical 
examination is  necessary for  the exclusion of  connective  tissue 
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disease,  drug intake and occupational/  environmental  exposure. 
The main aim is to differentiate from 
1. IIP or non-IIP 
2. IPF and non-IPF 
I
However,  it  must  be remembered that  a  confident  clinical 
diagnosis  of  IPF  has  a  very  good  specificity  (97%)  but  poor 
sensitivity (62%). Use of HRCT improves the sensitivity to 78.5% 
(Raghu et al) with a specificity of 90% with expert evaluation; one 
third to a quarter of patients cannot be confidently diagnosed on 
clinical  and  radiologic  grounds  and  will  require  a  surgical  lung 
biopsy.  Clinical  features  and  radiology perform even  poorer  for 
non-IPF IIP’s (88 and 40% and 59% and 40%). The importance of 
the clinical evaluation, cannot, thus be overstressed. 
I. Age 
A. Paediatric ILD’S 
i. Known aetiology 
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a. Hypersensitivity  pneumonitis  (and  other  environmental 
exposures) 
b. Lipid storage diseases 
c. Lipoid pneumonia 
ILD mimics are important and need to be ruled out 
d. Aspiration syndromes 
e. Chronic infection (viral, bacterial, fungal, parasitic) 
f. Bronchopulmonary dysplasia 
B
ii. Unknown aetiology 
a. Primary pulmonary: UIP/DIP/ NSIP/LIP/COP 
IPH/ Lymphatic disorders/ alveolar microlithiasis/ PIE 
b. Systemic  disorders:  CT-ILD/  Malignancies/  histiocytosis/ 
neurocutaneous syndromes/ sarcoidosis
Unique forms of DPLD in children include: 
a. Persistent  Tachypnea  of  infancy  (PTI)/neuroendocrine  cell 
hyperplasia of infancy (NEHI). 
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b. Follicular bronchitis/chronic bronchiolitis 
c. Cellular interstitial pneumonitis of infancy 
d. Acute idiopathic pulmonary haemorrhage of infancy (AIPHI) 
e. Chronic pneumonitis of infancy 
f. Idiopathic pulmonary fibrosis of infancy 
g. Familial desquamative interstitial pneumonitis (DIP) 
h. Surfactant  protein  abnormalities/congenital  alveolar 
proteinosis 
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B. Age - 20-40 Years 
Sarcoidosis 
Connective tissue disease-associated ILD 
Lymphangioleiomyomatosis 
Pulmonary Langerhans cell histiocytosis 
Inherited forms of ILD 
Alveolar microlithiasis 
C. Age >50 Years 
IPF – approx 2/3 of pts are >60 years old at time of diagnosis 
II. Sex 
Certain ILD’S preferentially affect one gender 
A. Male 
a. Occupational ILD’S 
b. PLCH 
c. RB-ILD 
d. CT-ILD related to rheumatoid arthritis 
e. Idiopathic pulmonary fibrosis 
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 B.Women 
a. Connective tissue related ILD 
b. Lymphangioleiomyomatosis (pre-menopausal females) 
c. Hermansky-Pudlak syndrome 
III. Depending on the mode of presentation
A. Acute presentation (days to weeks) 
1. Acute idiopathic interstitial pneumonia 
2. Accelerated presentation of UIP (Hamman-Rich syndrome) 
3. Eosinophilic pneumonia 
4. Hypersensitivity pneumonitis 
5. Diffuse alveolar haemorrhage 
6. Drug related ILD’S/ Toxic gases, fume related BOP 
7. COP 
8. Syndromic  presentations  of  sarcoidosis  (Lofgren  and 
Heefort’s).  In  acute  ILD’S,  great  care  is  required  to  rule  out 
infections and congestive cardiac failure. 
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B. Sub-acute presentation (weeks to months) 
1. Sarcoidosis 
2. Drug induced ILD 
3. COP 
4. CT-ILD 
C. Chronic presentation (months to years) 
1.  IPF 
2. CT-ILD 
3. Chronic hypersensitivity pneumonitis 
4. Pneumoconiosis (silicosis/ asbestosis)  
Episodic DPLD’S 
1. Eosinophilic pneumonia 
2.  Vasculitis 
3. Alveolar haemorrhage 
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4. Hypersensitivity pneumonitis 
5. Cryptogenic organising pneumonia 
C
IDIOPATHIC INTERSTITIAL PNEUMONIA             
Liebow, in 1975, classified idiopathic interstitial pneumonias (IIP) 
according  to  the  histopathologic  patterns.  Since  then,  there  has  been 
considerable change in the understanding of interstitial lung diseases that 
led  to  a  significant  change  in  this  classification  system.  Recently, 
Katzenstein and co-workers have suggested a classification that included 
not  only  chronic  interstitial  pneumonia  (usual  interstitial  pneumonia  - 
UIP  and  desquamative  interstitial  pneumonia-DIP),  but  also  acute 
interstitial   pneumonia  (AIP)  and  Non  specific  interstitial  pneumonia 
(NSIP) Travis and Colby have agreed upon Katzenstein classification but 
also  have  accepted  bronchiolitis  obliterans  organizing  pneumonia 
(BOOP) as a pattern of IIP.
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HISTOLOGICAL AND CLINICAL CLASSIFICATION 
OF IDIOPATHIC INTERSTITIAL PNEUMONIAS
HISTOLOGICAL PATTERNS Clinical, Radiological, Pathological 
diagnoses
Usual interstitial pneumonia Idiopathic pulmonary 
fibrosis/cryptogenic fibrosing 
alveolitis
Nonspecific interstitial pneumonia Nonspecific interstitial pneumonia 
(provisional)
Organizing pneumonia Cryptogenic organizing pneumonia+
Diffuse alveolar damage Acute interstitial pneumonia
Respiratory bronchiolitis Respiratory bronchiolitis interstitial 
lung disease
Desquamative interstitial pneumoniaDesquamative interstitial pneumonia
Lymphocytic interstitial pneumonia Lymphocytic interstitial pneumonia
Unclassifiable interstitial pneumonia: some cases are unclassifiable 
for a variety of reasons.
This  group  represents  a  heterogeneous  group  with  poorly 
characterized clinical and radiological features that need further study.
COP  is  the  preferred  term,  but  is  synonymous  with  idiopathic 
bronchiolitis obliterans organizing pneumonia.
b
Development  of  the  (histologic)  idiopathic  interstitial  pneumonia 
classification13,14,15
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UIP=usual interstitial pneumonia; DAD=diffuse alveolar damage; 
NSIP=non-specific interstitial pneumonia; DIP=desquamative interstitial 
pneumonia;  RB=respiratory  bronchiolitis;  BIP=bronchiolitis  obliterans 
interstitial  pneumonia;  OP=organizing  pneumonia;  LIP=lymphoid 
interstitial pneumonia; LPD=lympho proliferative disease (not considered 
a  diffuse  lung  disease);  GIP=gaint  cell  interstitial  pneumonia  ; 
HMF=heavy metal fibrosis, no longer grouped with diffuse lung disease.
Lymphoid  interstitial  pneumonia  was  originally  included  in  this 
category, then excluded, then included again. 
Collagen vascular  diseases are a group of diseases with specific 
autoimmune characteristics that affect several organs including the lungs . 
 
Intrathoracic  manifestations are  frequent  and may be asymptomatic  or 
symptomatic, with varied degrees of severity. The pattern and frequency 
of the Intrathoracic involvement depend on the specific type of collagen 
vascular disease and may include one or more pulmonary compartments 
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such  as  alveolus,  interstitium,  vessels,  lymphatic  tissue,  airways  and 
pleura20.
The most frequent pulmonary manifestations are diffuse interstitial 
pneumonias  and pulmonary hypertension  which as a whole represent the 
main causes of mortality and morbidity in these patients . It is important 
to note that pulmonary abnormalities in patients with collagen vascular 
disease may be due not only to the underlying disease, but also result 
from its treatment, and include drug reaction and infection by bacteria or 
opportunistic  organisms,  such  as Pneumocystis  jiroveci,  and  atypical 
mycobacteria as a result of immunosuppression.  
The  collagen  vascular  diseases  that  most  commonly  result  in 
interstitial  lung  disease  are  rheumatoid  arthritis,  progressive  systemic 
sclerosis,  systemic  lupus  erythematosus,  dermatopolymyositis,  mixed 
connective tissue disease and Sjögren syndrome.
Interstitial  pneumonias represent  the  most  common Intrathoracic 
manifestations of collagen vascular disease . Collagen vascular diseases 
may  be  associated  with  virtually  all  patterns  of  diffuse  interstitial 
pneumonia and may progress to pulmonary fibrosis . The histological 
classification  is  similar  to  that  of  idiopathic  interstitial  pneumonias 
including: a)  patterns  of  chronic  progression  - usual  interstitial 
pneumonia,  non-specific  interstitial  pneumonia  and  lymphocytic 
interstitial  pneumonia; b) pattern of sub acute progression - organizing 
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pneumonia (also known as bronchiolitis obliterans organizing pneumonia 
—BOOP); c) pattern of acute progression of pulmonary injury - diffuse 
alveolar damage.
High-resolution  CT  manifestations  of  interstitial  pneumonias  in 
patients  with  collagen  vascular  diseases  also  are  similar  to  the  ones 
described for patients with idiopathic disease. Collagen vascular diseases 
most  frequently  associated  with  interstitial  pneumonia  are:21,22 
rheumatoid  arthritis,  progressive  systemic  sclerosis  (scleroderma)  and 
dermatopolymyositis.
In general,  non-specific interstitial pneumonia is the most common 
pattern  of  interstitial  pneumonia  in  patients  with  collagen  vascular 
diseases. In patients with rheumatoid arthritis23,24, however, it seems that 
the pattern of usual interstitial pneumonia is the most frequent one. On 
the other hand, lymphocytic interstitial pneumonia, although rare, is most 
common in patients with Sjögren's syndrome, while the diffuse alveolar 
damage pattern is  more  frequent  in  patients  with dermatopolymyositis 
and systemic lupus erythematosus.
a
In general, chronic progressive interstitial pneumonias in collagen 
vascular diseases have a better prognosis than those of idiopathic nature, 
with  a  better  five  year  survival  rate.  However,  cases  of  unfavourable 
progression  in  patients  with  collagen  vascular  disease  and  interstitial 
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pulmonary  involvement  with  no  response  to  the  therapy  are  not 
infrequent. Similarly to the idiopathic form of disease, the non-specific 
interstitial  pneumonia pattern in collagen vascular  disease has a better 
prognosis than the pattern of usual interstitial pneumonia. 
The concomitant presence of more than one pattern of interstitial 
pneumonia, particularly the association between non-specific interstitial 
pneumonia and organizing pneumonia  (BOOP) is  not  rare  in  collagen 
vascular  disease,  and  is  most  common  in  patients  with 
dermatopolymyositis and mixed connective tissue disease. Generally, the 
pattern of diffuse alveolar damage is associated with poor prognosis, both 
in  patients  with idiopathic  disease and patients  with collagen vascular 
disease .
Interstitial  pneumonias  may  precede  the  clinical  onset  of  the 
collagen vascular disease for a period of three months up to five years, 
usually with a pattern of non-specific interstitial  pneumonia or acutely 
with a pattern of diffuse alveolar damage. Patients with collagen vascular 
disease,  especially  rheumatoid  arthritis,  scleroderma  and 
dermatopolymyositis,  may progress with acute  exacerbation of  fibrotic 
interstitial pneumonia. 
 
Most frequently, acute pulmonary injury manifests histologically 
as  diffuse  alveolar  damage  superimposed  on  underlying  pulmonary 
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fibrosis (generally usual interstitial pneumonia or non-specific interstitial 
pneumonia patterns).  HRCT findings of  acute  exacerbation of  chronic 
progressive  interstitial  pneumonia  in  patients  with  collagen  vascular 
disease  consist  in  diffuse  areas  of  ground-glass  attenuation,  with  or 
without  associated  smooth  inter-  and  intralobular  lines  resulting  in 
a crazy  paving pattern  associated  with  signs  of  fibrosis  from the  pre-
existing  interstitial  pneumonia  (distortion  of  pulmonary  architecture, 
traction bronchiectasis, reticulation and honeycombing).
Areas of focal or bilateral dependent consolidation may be present. 
The main differential diagnosis for ground-glass attenuation at HRCT in 
patients with collagen vascular disease and fibrotic interstitial pneumonia 
includes  opportunistic  infections  (particularly  by Pneumocystis)  and 
drug-induced  lung  disease.  Consolidation  may  be  due  to  organizing 
pneumonia or an infectious process (by bacteria, mycobacteria or fungi). 
Sarcoidosis  is  a  multisystem  granulomatous  disorder  of  unknown 
aetiology most  commonly  affecting  young adults  and presenting  most 
frequently  with bilateral  hilar  lymphadenopathy,  pulmonary infiltration 
and skin or eye lesions.    
 
 
The  diagnosis  is  established  most  securely  when  clinic 
radiographic  findings  are  supported  by  histological  evidence  of 
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widespread noncaseating   epithelioid granulomas in more than one organ 
or  a  positive  Kveim–Siltzbach  skin  test.  Immunological  features  are 
depression  of  delayed-type  hypersensitivity,  suggesting  impaired  cell-
mediated immunity, and raised or abnormal Immunoglobulin’s. 
Many types of abnormality may be seen on the chest film and these 
may be classified as follows:25
1 disseminated miliary lesions 
2 disseminated nodular lesions 
3 linear type of infiltration extending fan-wise from the hilum;
4 diffuse and confluent patchy shadows;
5 diffuse fibrosis 
6 diffuse fibrosis with cavitation 
7 diffuse ground-glass shadowing 
8 changes  similar  to  chronic  tuberculosis  as  regards  location  and 
distribution;
9 bilateral  confluent  massive  opacities  resembling  areas  of 
pneumonia;
10 atelectasis.
.
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Transbronchial biopsy of lung and bronchial wall via the flexible 
fiberoptic bronchoscope is the procedure of choice in the diagnosis of 
diffuse  pulmonary  abnormality  of  probable  sarcoid  aetiology  and  is 
employed especially if there are cogent reasons for securing a diagnosis 
earlier than can be expected from the Kveim test. A minimum of four 
lung  biopsies  by  this  method  optimizes  the  chances  of  securing  a 
diagnosis.
Pulmonary alveolar microlithiasis is a disease that is often familial 
and characterized by a radiographic appearance of very fine, sand-like 
mottling  uniformly  distributed  through  both  lungs.  This  mottling 
represents an extensive. Intra-alveolar  deposit  of  calcium-containing 
bodies. Despite extensive radiographic changes, symptoms at the time of 
discovery  are  often  minimal  or  absent,  but  later  there  is  gradual 
progression  to  respiratory  failure  and  cor  Pulmonale. Although  not 
usually  required,  bronchoalveolar  lavage  or  biopsy  can  confirm  the 
diagnosis. Biopsy shows calcified spherules filling alveolar spaces.
Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, 
is  a  spectrum  of  interstitial,  alveolar,  and  bronchiolar  lung  diseases 
resulting   from immunologically induced inflammation in response to 
inhalation of a wide variety of different materials that are usually organic 
or low-molecular weight chemical antigens (or haptens) that may lead to 
irreversible lung damage.
30
 A  lung  biopsy  specimen  is  generally  required  when  there  is 
significant doubt about the diagnosis. Transbronchial lung biopsies often 
do  not  provide  sufficient  material  to  fully  establish  the  presence  and 
interrelationships  of  granulomas,  bronchiolitis,  and  interstitial 
inflammation,  so either open or thoroscopically obtained lung biopsies 
may be necessary.
MATERIALS AND METHODS
This prospective study was organized in department of Thoracic 
medicine in association with department of Rheumatology, Government 
General Hospital,chennai. Subjects were recruited from the thoracic and 
Rheumatology outpatient clinic of our hospital.  Approval from Medical 
Ethical Committee has been obtained
The study period extended from February 2009 to October 2009 
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DESIGN OF THE STUDY:
Prospective study. 
INCLUSION CRITERIA
1. Radiologically suspected cases of DPLD.
2. Age > 12 years.
3. Sex- Both genders.
Presence of respiratory signs and symptoms suggestive of DPLD
                5. willing for study with informed consent
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EXCLUSION CRITERIA
Uncorrectable  hypoxemia/hypercapnia
Unstable myocardium
Uncorrectable bleeding tendency
Tracheal stenosis
Poorly controlled asthma
     7.  Age less than 12
     8. Patients with elevated renal parameters
9. Uncooperative patient
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METHODOLOGY
Patients who were fulfilling the inclusion criteria were included for 
the  study  after  obtaining  the  written   informed  consent.They  were 
subjected to the following investigation
1. THOROUGH CLINICAL EVALUATION
2. HRCT CHEST
3. PULMONARY FUNCTION TEST
4. BRONCHOSCOPY AND TBLB
THOROUGH CLINICAL EVALUATION
In essence, without proper medical history all diffuse parenchymal 
lung diseases are of unknown cause. For an accurate diagnosis, there is 
no substitute for complete clinical evaluation. This should be considered 
as the key diagnostic steps in the evaluation of patient who has DPLD.
Thorough history elicitation with comprehensive evaluation of the 
chief  complaint  and  comprehensive  review  of  multiple  systems  were 
done. 
Medical  history  was  taken  with  special  reference  to  previous 
cardiopulmonary disease, cough, exertional dyspnea, sputum, chest pain 
and risk factors for pulmonary disease, such as smoking.
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 Then followed by exhaustive review of past medical, social, family 
and  occupational  histories  with  an  exploration  of  all  potential 
environmental exposures were done. The clues that surface during this 
evaluation help to narrow the broad differential diagnosis to few possible 
disorders as per ATS recommendation.
HRCT CHEST
The  patients  were  then  subjected  to  the  High-resolution 
computed tomography (HRCT) in  the   supine position,  holding 
breath  at  deep  inspiration,  without  contrast  medium.  Prone 
sections were taken when posterior  images obtained on supine 
sections  were  suspected  of  having  artefacts  due  to  gravity 
dependent perfusion. The added value of HRCT scanning in DPLD 
depends  upon  its  ability  to  increase  confidence  of  a  specific 
diagnosis  by  characterisation  and  profusion  of  lesion  on 
representative anatomical level, to alter  patient management and 
if possible, to influence the outcome
PULMONARY FUNCTION TESTS
After  completing the physical  examination  and HRCT of those 
who have fulfilled criteria, were subjected to  pulmonary function test. 
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The various manoeuvres of spirometry  were explained and practically 
demonstrated to them.
d
PFT was deferred to those persons who were suspected of having 
symptoms of   respiratory tract  infection.  A course of  antibiotics  were 
given to them and asked to come for the next session for the completion 
of  PFT. 
BRONCHOSCOPY AND TRANSBRONCHIAL LUNG BIOPSY
After above procedures, patient was assessed for bronchoscopy and 
transbronchial lung biopsy. Consent for bronchoscopy and biopsy were 
obtained. Thirty two patients were studied. Patients were selected on the 
basis of a chest radiography compatible with diffuse lung disease without 
prior tissue diagnosis. 
Under  topical  anaesthesia  transbronchial  lung  biopsy  and 
bronchoalveolar lavage was carried through  fiberoptic bronchoscope at 
same  setting.  All  patients   were  given  glycopyrrolate(.2mg)  as 
premedication.  Fluoroscopy was not employed. For all patients BAL and 
TBLB  was  done  in  same  setting.  BAL  was  done  in  middle  lobe  or 
lingula. TBLB were obtained from the lower lobe segments on the side of 
greatest involvement, if any, or from the right lower lobe if disease was 
distributed equally  by lung imaging.  Four  to six  biopsies  taken at  the 
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same time. In this procedure, the upper lobes, middle   lobe and lingula 
were avoided because,  without  parietal  pleural  pain as  a  warning,  the 
major fissure may be transversed, with resultant pneumothorax. 
m
Samples were sent for cytology,  cell  count,  microbiological 
study and histopathologic analysis in government general hospital. 
For all patient chest x ray was taken after the procedure, to rule 
out  any  procedure  related  pneumothorax.  Patient  were  under 
medical  supervision  to  pick  up  any  procedure  related 
complications.
Transbronchial lung biopsy26,27
Transbronchial  (sometimes  referred  to  as  ‘bronchoscopic’)  lung 
biopsies  are  made  beyond  the  limits  of  direct  vision  and  may  be 
conveniently  carried  out  under  fluoroscopic  control  using  a  C-arm or 
other suitable device, although some bronchoscopist  have been content 
to work without any such assistance. Where there is diffuse disease that is 
bilateral, the tip of a larger Channel bronchoscope may be wedged into a 
laterally placed segmental bronchus in either lower lobe, as these usually 
accept  the  forceps  comfortably.  At  this  point,  5mL  of1:  20000 
epinephrine solution is injected into the chosen segmental orifice in the 
belief that this diminishes the likelihood of serious bleeding  .The largest 
possible  toothed  biopsy  forceps  are  then  passed  through  the  same 
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segmental opening, while the end of the bronchoscope remains wedged 
into that segment, the shaft of the bronchoscope nearest the patient being 
held  by  the  assistant,  with  gentle  inward  pressure,  so  that  the 
bronchoscopist is free to advance the forceps.  If  the forceps reach the 
extreme periphery of the lung, Pleuritic pain may be felt and the forceps 
are withdrawn a few centimetres to reduce the chance of pneumothorax. 
a
If  the forceps are  arrested early   in their  journey,  another  basal 
segment is tried instead, as too proximal a biopsy runs a small risk of 
damaging  a  larger  blood  vessel.  When  the  forceps  appear  to  be  well 
situated towards the lung periphery, the patient is asked to ‘take a deep 
breath in and hold it’ and the assistant is given the instruction ‘open’. and 
they are then pushed gently forwards until resistance is felt, whereupon 
the patient is asked to ‘let all your air out’ and the assistant is given the 
instruction ‘close’ when expiration is seen to be complete. The forceps 
are then firmly withdrawn. An elastic tug followed by a feeling of ‘give’ 
is sensed and lung tissue may be seen to be pulled and to recoil back into 
place on the screen. This is usually a sign that a satisfactory biopsy has 
been obtained. The biopsy material is then placed in fixative(formalin) 
for histopathology or normal saline for microbiology.
38
Transbronchial biopsy: mechanism whereby acinar
tissue may be obtained
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RESULTS
In our study 50 patients were screened for  Diffuse Parenchymal 
Lung Diseases. Out of which 32 patients were taken up for the study after 
satisfying eligible criteria.  Remaining patients were excluded from the 
study group based on exclusion criteria.
AGE
In our study population age group ranges from 14-70 years.
Table 1
Age Group ( Years )
No of Patients
Percentage (%)
<20
20-40
40-60
>60
2
11
17
40
26.25
34.37
53.12
6.25
TOTAL
32
100
Maximum number  of  patients    presented  between  the  ages  of 
40-60 years. The mean age distribution found in our study is 42 year. 
4
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QSEX
Table 2
SEX No of Patients Percentage (%)
Male
Female
13
19
40.62
59.37
Total 32 100
The selected  patients  consisted  of  59.37% Females  and 40.62% 
males.
DISEASE(Etiologic) CLASSIFICATION:
In my study patients are grouped according to aetiology through 
clinical and radiological grounds
(Table 3)
DISEASE NO OF PATIENTS PERCENTAGE
KNOWN ETIOGY 15 46.875
UNKNOWN ETILOGY 10 31.25
GRANULAMATOUS 
LUNG DISEASE
6 18.75
RARER FORM 1 3.125
42
TOTAL 32 100
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  
As the above pie diagram shows  in my study most predominant 
HRCT finding is mixed pattern.
DISEASE CLASSIFICATION28:
DPLD  was  subdivided  into  four  subgroups  according  to 
aetilology.1.DPLD  of  unknown  cause  which  includes  IIP,  2.DPLD 
associated  with  identifiable  cause,  such  as  environmental  exposure  or 
systemic  illness  such  as  collagen  vascular  diseases,3.granulamatous 
diseases  such  as  sarcoidosis,  hypersensitivity  pneumonitis,  and 
tuberculosis, 4.few rarer form of DPLD such as LCH , LAM,and PAM.
Out  of  32  cases  15  cases  are  associated  with  known causes,10 
cases  are  of  unknown  etiology  classified  as  idiopathic  interstitial 
pneumonia, six cases are granulomatous lung disease and  1 cases are 
classified in rarer form of DPLD.
In  15  cases  of  known  etiology  group,  4  cases  are  known 
rheumatoid arthritis patient,1 case was SLE, dermatomyositis 1 case, 3 
cases are systemic sclerosis,  2 cases are overlap syndrome,1 case was 
drug  induced  DPLD(methotrexate)  and  2  cases  was  Lymphangitis 
carcinomatosis.
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Out of 10 cases of IIP 5 cases are smoking related, 5 cases with 
unknown etiology.
In 6 cases of  granulomatous lung disease 3 cases are  suspected 
sarcoidosis and 3 are suspected tuberculosis(pre biopsy diagnosis).
s
In  rarer  form  of  DPLD  one  case  was  pulmonary  alveolar 
microlithiasis.
CLINICAL FEATURE:
The  predominant symptom found in majority of the study cases 
are  Exertional dyspnoea(88.89%),  followed  by  cough(50%)  and chest 
pain(25%)  fever 12(%)cases.  Bibasilar crackles heard in 16 cases out of 
32 cases.
Extra pulmonary symptoms are Dyspepsia, Dysphagia, Reynaud’s 
phenomenon,  inflammatory  arthritis,  subcutaneous  nodules,  Sicca 
syndrome,  Skin  changes  like  rash,  discolouration  and  thickening, 
proximal  muscle  weakness,  etc  .  These  above-mentioned  symptoms 
present  concomitantly  in  our  cases  and  these  symptoms  have  either 
preceded or accompanied with respiratory illness.
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Age group versus clinical diagnosis   
(Table 4)
Age Group Unknown 
Etilogy
Known Etilogy Granulamatous 
Lung Disease
Rarer 
Form
<20 0 0 1 1
20-40 3 7 2 0
40-60 6 7 3
>60 1 1 0 0
Total 10 15 6 1
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AGE GROUP VERSUS TRANSBRONCHIAL LUNG BIOPSY 
(Table 5)
Age 
group
Nsip Sarcoi-
dosis
Tb Pam Lymphangitis 
carcinomatosa
Not 
contribuat-
ory
Total
<20 0 0 1 1 0 0 2
20-40 4 0 0 0 0 7 11
40-60 6 1 0 0 1 7 15
>60 0 0 0 0 0 2 2
Total 10 1 1 1 1 16 30
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DISCUSSION
Diffuse parenchymal lung disesase (DPLD) is a term given to a 
heterogeneous group of clinical entities  that share the following features: 
dyspnea as the main symptom; hypoxemia; restrictive Ventilatory defect 
pattern  in  pulmonary  function  tests;  and  the  presence  of  reticular, 
nodular,  reticulonodular,  or  ground glass-appearing infiltrates  on chest 
roentgenogram.
Under the heading of diffuse parenchymal lung disease, there are 
diverse aetiologies’ that lead to similar histologic patterns. These patterns 
are the main determinants of the clinical outcome of the patients and are 
also important in the differential diagnosis, mainly from other diseases 
that also affect interstitial compartment of the lungs.
Many patients with DPLD have inadequate information about the 
disease  process,  an  imprecise  diagnosis,  unsatisfactory  treatment  or 
unacceptable side effects associated with therapy, and poorly controlled 
symptoms of  progressive illness.  Establishing an accurate  diagnosis  is 
necessary for  clinician to plan appropriate management as well  as  the 
patient and his/her family can be provided with reasonable expectations 
about prognosis and outcome from therapy. 
a
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The  diagnosis  of  individual  disease  is  made  after  a  careful 
consideration  of  clinical   features(thorough  history  and  examination), 
radiology and Histopathological examination
In  my  study  DPLD  was  subdivided  into  IIP,DPLD  of  known 
causes, granulomatous disease and  rarer form of DPLD such as LCH , 
LAM,and PAM.
Out of 32 cases 15 cases are of known causes such as collagen 
vascular  disease ,drug induced DPLD(methotrexate)  and Lymphangitis 
carcinomatosis,10  cases  are  classified  as  idiopathic  interstitial 
pneumonia, six cases are granulomatous lung disease and  1 cases are 
classified in rarer form. In 12 cases of collagen vascular lung disease 4 
cases  are  known  rheumatoid  arthritis  patient,1  case  was 
SLE,dermatomyositis 1 case, 3 cases are systemic sclerosis, 2 cases are 
overlap syndrome.
Out of 10 cases of IIP 5 cases are smoking related, 5 cases with 
unknown etiology.
In 6 cases of  granulomatous lung disease 3 cases are  suspected 
sarcoidosis and 3 are suspected tuberculosis(pre biopsy diagnosis).
In rarer form 1 case was pulmonary alveolar microlithiasis,  Our 
study  principally  focuses  mainly  on  diagnostic  yield  of  transbronchial 
lung biopsy in assessing the prognosis and excluding the other diseases. 
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Out of 32 cases .in my study 59.37 %(19) were female and 40.62%(13) 
were male. Maximum number of patients   presented between the ages of 
40-60 years. The mean  age distribution found in our study is42 year.
Most cases presented with mixed pattern in HRCT. Out of 32 cases 
for 14 cases we got specific diagnosis which is around 43.75%. among 
which NSIP in 10 ,tuberculosis in 1,sarcoidosis in 1,pulmonary alveolar 
microlithiasis  in  1,lymphanjitis  carcinomatosis  in  1,for  16  cases  we 
couldn’t  get  specific  diagnosis.  And  for  2  cases  the  biopsy  sample 
reported as inadequate.
Out  of  32 cases who had undergone TBLB one case developed 
pneumothorax  after  the  procedure  which  did  not  require  intercostal 
drainage.
In Ailani RK29 et al study histopathologic diagnosis is obtained in 
77%. Complications encounted were haemorrhage (23%), pneumothorax 
(3%), and post biopsy chest pain in (3%). 
Comparing to above study in  our study histopathological diagnosis 
is obtained in 43.75%.complication in one patient(3%) and none of the 
patient developed haemorrhage.
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 CONCLUSION 
Transbronchial  lung  biopsy  is  a   relatively  safe  method  for 
diagnosing specific diffuse parenchymal lung disease and for obtaining 
histological  pulmonary  specimens  which   aids  in  excluding  other 
etiologic causes of diffuse parenchymal lung disease. 
We  recommend  use  of  this  diagnostic  procedure  as  a 
supplementary to HRCT and clinical examination. but more number of 
cases  are  needed  to  prove  definitely  acceptable  outcomes  so  that  the 
technique can be a part of diagnosing diffuse parenchymal lung disease.
We  conclude  that,  to  determine  the  prognosis  and  appropriate 
therapeutic intervention for the patient, accurate pathological diagnosis in 
conjugation with clinical and radiological finding is mandatory.
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ABBREVIATION
ATS American Thoracic Society
BAL           Bronchoalveolar Lavage
BIP              Bronchiolitis obliterans organising pneumonia
CVD Collagen Vascular Disease
COP Cryptogenic Organizing Pneumonia
DPLD             Diffuse parenchymal lung disease
DAD            Diffuse alveolar damage
DIP              Desquamative Interstitial Pneumonitis
GIP              Gaint Cell interstitial pneumonia
HRCT           High resolution contrast CT
ILD Interstitial lung diseases
LIP Lymphocytic Interstitial Pneumonitis
MCTD Mixed Connective Tissue Disease 
NSIP Non-Specific Interstitial Pneumonitis
PFT Pulmonary Function Test 
PM/DM Polymyositis/Dermatmyositis
RA Rheumatoid Arthritis
RBILD Respiratory Bronchiolitis Interstitial Lung Disease
SLE Systemic Lupus Erythematosus
SS Systemic Sclerosis
UIP Usual interstitial pneumonia
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